Emerging combination therapeutic strategies designed to selectively disrupt HR repair in cancer cells and make them vulnerable to PARP inhibitors have been evaluated in preclinical and early clinical trials in a variety of cancer types, including ovarian cancer. This evidence concerns the gene PARP1 and cancer.